Corvus Pharmaceuticals, Inc.
CRVSCorvus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing targeted therapies for cancer and immuno-oncology. Founded in 2014 and based in Burlingame, California, the company concentrates on designing small molecule drugs intended to modulate the immune system to improve cancer treatment outcomes.
Company News
Corvus Pharmaceuticals director David Scott Moore purchased 21,700 common shares for approximately $250,000 on June 11, 2026, marking his first investment in the company since joining as a director in October. Moore also received 15,000 stock options vesting in a year. The insider buy is viewed as a positive signal, though it should be considered...
The peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expecte...
Three rapid-growth stocks have significantly outperformed the broader market in early 2026. Corvus Pharmaceuticals surged 188% YTD on positive Phase 1 trial data for its atopic dermatitis drug candidate soquelitinib, with a Phase 2 trial planned for early 2026. New Era Energy & Digital jumped 114% YTD following strategic partnerships in the data ...
Corvus Pharmaceuticals successfully closed an upsized public offering of 9,085,778 shares at $22.15 per share, generating approximately $201.2 million in gross proceeds. The company plans to use the net proceeds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes.
Corvus Pharmaceuticals priced an upsized underwritten public offering of 7.9 million shares at $22.15 per share, raising approximately $175 million in gross proceeds. The company plans to use the funds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes. The offering is e...
